A5037602130- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Thyroid Cancer Diagnosis and Treatment
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Thyroid and Parathyroid Surgery
- Head and Neck Anomalies
- Diet and metabolism studies
- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Growth Hormone and Insulin-like Growth Factors
- Pancreatic function and diabetes
- Adipose Tissue and Metabolism
- Eating Disorders and Behaviors
- Wound Healing and Treatments
- Congenital heart defects research
- Thyroid Disorders and Treatments
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Bariatric Surgery and Outcomes
- BRCA gene mutations in cancer
- Diabetes Management and Education
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetic Foot Ulcer Assessment and Management
- Adrenal Hormones and Disorders
- Chronic Lymphocytic Leukemia Research
Hospital Universitario Son Espases
2013-2025
Universitat de les Illes Balears
2022
Columbus Oncology and Hematology Associates
2014
Indianapolis Zoo
2014
Hospital Universitario Son Dureta
2007-2010
Universidad de Alcalá
2005
Hospital Universitario Reina Sofía
1999-2004
Unité de Nutrition Humaine
2001
Compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients type 2 diabetes. The primary objective compared dulaglutide 1.5 mg metformin on change from baseline glycosylated hemoglobin A1c (HbA1c) at 26 weeks.This 52-week double-blind study randomized subcutaneous mg, 0.75 or metformin. Patients (N = 807) had HbA1c ≥6.5% (≥48 mmol/mol) ≤9.5% (≤80 diet exercise alone low-dose oral antihyperglycemic medication (OAM)...
Importance Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy safety adding tirzepatide vs prandial insulin to in patients with inadequate glycemic control basal have not been described. Objective To assess efficacy lispro as an adjunctive therapy glargine. Design, Setting, Participants This open-label, phase 3b clinical trial was conducted at 135 sites 15 countries (participants...
Aims: This study was undertaken to evaluate (i) factors associated with patient‐reported hypoglycaemia; (ii) association of hypoglycaemic symptoms treatment satisfaction and barriers adherence (iii) between satisfaction, glycaemic control among patients type 2 diabetes who added a sulphonylurea or thiazolidinedione ongoing metformin. Methods: observational, cross‐sectional, multicentre conducted in seven countries (Finland, France, Germany, Norway, Poland, Spain UK) from June 2006 February...
To evaluate insulin-secretion kinetics and insulin sensitivity in cystic fibrosis (CF) patients with normal glucose tolerance (CF-NGT), impaired (CF-IGT) or CF-related diabetes (CFRD), the potential effects of moderate hyperglycemia on clinical nutritional status.Cross-sectional study including 50 outpatients CF. Patients underwent both oral (OGGT) intravenous (IVGTT) tests order to assess secretion peripheral sensitivity. Homeostasis assessment model OGGT were used investigate Forced...
To evaluate in a real-world setting the effectiveness and tolerability of available GLP-1 RA drugs patients with type 2 diabetes after prolonged follow-up.Observational, retrospective, single-centre study starting therapy. Change HbA1c, fasting plasma glucose (FPG) body mass index (BMI) along gastrointestinal (GI) adverse events withdrawal from therapy were evaluated. Lack efficacy according to prespecified goals was also measured.A total 735 included, mean age 59.7 years, duration 9.01...
Ambulatory blood pressure monitoring (ABPM) allows determining of the nocturnal fall (NBPF). An NBPF below 10% (nondipper pattern) has been related to increased cardiovascular risk, and it is a common finding in type 2 diabetic hypertensive patients. The authors evaluated impact on 24‐hour pressure, NBPF, albuminuria olmesartan 40 mg, administered morning‐ vs nocturnal‐based dosing scheme, patients with newly diagnosed hypertension. Using crossover design, (42.1% men) received mg once daily...
This study aimed to describe utilization patterns, persistence, resource and costs in patients with type 2 diabetes mellitus initiating treatment glucagon-like peptide 1 receptor agonists routine clinical practice Spain. retrospective of medical records the Big-Pac database identified adults starting once-weekly (QW) dulaglutide, exenatide-QW or once-daily liraglutide between November 2015 30 June 2017. Patients were followed for up 18 months from initiation. Data on characteristics...
Abstract Background Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide approved in US EU for treatment type 2 diabetes (T2D) obesity. In SURPASS clinical trial program T2D, demonstrated greater improvements glycemic control, body weight reduction other cardiometabolic factors versus placebo, subcutaneous semaglutide 1 mg,...
Neck recurrence of papillary thyroid cancer (PTC) is frequently detected after initial surgery. The management these lesions may include rescue surgery (RS) or minimally invasive techniques in selected patients, but comparative studies evaluating the effectiveness and safety are lacking. In this paper, we compared ultrasound-guided ethanol ablation (EA) patients to RS a matched cohort.We retrospectively 41 PTC without known distant metastases, who underwent EA (matched reference group), had...
Tirzepatide (TZP) is a once weekly GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes (T2D). In this 52-wk open-label, multicenter, Phase 3b study, 1428 patients with T2D (mean baseline [BL] age 59 y; duration 14 HbA1c 8.8%; BMI 33 kg/m2; insulin glargine (iGlar) dose 46 IU/day) were randomized (1:1:1:3) to TZP (5, 10, 15 mg) or lispro (iLispro) TID, as an add-on iGlar ± metformin. Insulin doses titrated target fasting pre-prandial glucose 100-125 mg/dL. Primary efficacy...
Objective:Therapeutic guidelines recommend the combination of drugs as necessary to control type 2 diabetes (T2D). This research assessed effectiveness pioglitazone (Pio), metformin (Met) and sulfonylurea (SU) combinations in routine clinical practice.Research design methods:A nationwide, 12-month prospective, observational cohort study was performed 2294 patients with T2D (50.3% females, mean age: 61.1 years, body mass index: 30.2 kg/m2, time since diagnosis: 8.5 years) who started, at...